Kriya Highlights Positive Preclinical Data for KRIYA-586, a Gene Therapy Product Candidate for Thyroid Eye Disease (TED), at ESOPRS Annual Meeting – Preclinical data demonstrate pharmacodynamic activity of KRIYA-586, an investigational gene therapy which encodes for an anti-IGF1R antibody – – Kriya anticipates advancing KRIYA-586 into the...

Kriya Provides Update on Pipeline Progress Ahead of Company Presentation at 42nd Annual J.P. Morgan Healthcare Conference – Kriya anticipates up to 5 programs to enter clinic by the end of 2025 – – Current pipeline of gene therapies for common diseases spans three major therapeutics areas: ophthalmology, metabolic...